vs
Side-by-side financial comparison of Idexx Laboratories (IDXX) and Revvity (RVTY). Click either name above to swap in a different company.
Idexx Laboratories is the larger business by last-quarter revenue ($1.1B vs $772.1M, roughly 1.4× Revvity). Idexx Laboratories runs the higher net margin — 22.8% vs 12.7%, a 10.0% gap on every dollar of revenue. On growth, Idexx Laboratories posted the faster year-over-year revenue change (14.3% vs 5.9%). Idexx Laboratories produced more free cash flow last quarter ($326.3M vs $161.8M). Over the past eight quarters, Revvity's revenue compounded faster (9.0% CAGR vs 6.4%).
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions.
Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.
IDXX vs RVTY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $772.1M |
| Net Profit | $248.2M | $98.4M |
| Gross Margin | 60.3% | — |
| Operating Margin | 28.9% | 14.5% |
| Net Margin | 22.8% | 12.7% |
| Revenue YoY | 14.3% | 5.9% |
| Net Profit YoY | 14.8% | 3.9% |
| EPS (diluted) | $3.09 | $0.86 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $998.4M | $664.8M | ||
| Q4 24 | $954.3M | $729.4M | ||
| Q3 24 | $975.5M | $684.0M | ||
| Q2 24 | $1.0B | $691.7M | ||
| Q1 24 | $964.1M | $649.9M |
| Q4 25 | $248.2M | $98.4M | ||
| Q3 25 | $274.6M | $46.7M | ||
| Q2 25 | $294.0M | $53.9M | ||
| Q1 25 | $242.7M | $42.2M | ||
| Q4 24 | $216.1M | $94.6M | ||
| Q3 24 | $232.8M | $94.4M | ||
| Q2 24 | $203.3M | $55.4M | ||
| Q1 24 | $235.6M | $26.0M |
| Q4 25 | 60.3% | — | ||
| Q3 25 | 61.8% | 53.6% | ||
| Q2 25 | 62.6% | 54.5% | ||
| Q1 25 | 62.4% | 56.5% | ||
| Q4 24 | 59.8% | — | ||
| Q3 24 | 61.1% | 56.3% | ||
| Q2 24 | 61.7% | 55.7% | ||
| Q1 24 | 61.5% | 54.6% |
| Q4 25 | 28.9% | 14.5% | ||
| Q3 25 | 32.1% | 11.7% | ||
| Q2 25 | 33.6% | 12.6% | ||
| Q1 25 | 31.7% | 10.9% | ||
| Q4 24 | 27.4% | 16.3% | ||
| Q3 24 | 31.2% | 14.3% | ||
| Q2 24 | 26.3% | 12.4% | ||
| Q1 24 | 31.0% | 6.8% |
| Q4 25 | 22.8% | 12.7% | ||
| Q3 25 | 24.8% | 6.7% | ||
| Q2 25 | 26.5% | 7.5% | ||
| Q1 25 | 24.3% | 6.4% | ||
| Q4 24 | 22.7% | 13.0% | ||
| Q3 24 | 23.9% | 13.8% | ||
| Q2 24 | 20.3% | 8.0% | ||
| Q1 24 | 24.4% | 4.0% |
| Q4 25 | $3.09 | $0.86 | ||
| Q3 25 | $3.40 | $0.40 | ||
| Q2 25 | $3.63 | $0.46 | ||
| Q1 25 | $2.96 | $0.35 | ||
| Q4 24 | $2.62 | $0.77 | ||
| Q3 24 | $2.80 | $0.77 | ||
| Q2 24 | $2.44 | $0.45 | ||
| Q1 24 | $2.81 | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $180.1M | $919.9M |
| Total DebtLower is stronger | $450.0M | — |
| Stockholders' EquityBook value | $1.6B | $7.3B |
| Total Assets | $3.4B | $12.2B |
| Debt / EquityLower = less leverage | 0.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $180.1M | $919.9M | ||
| Q3 25 | $208.2M | $931.4M | ||
| Q2 25 | $164.6M | $991.8M | ||
| Q1 25 | $164.0M | $1.1B | ||
| Q4 24 | $288.3M | $1.2B | ||
| Q3 24 | $308.6M | $1.2B | ||
| Q2 24 | $401.6M | $2.0B | ||
| Q1 24 | $397.4M | $1.7B |
| Q4 25 | $450.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $617.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.6B | $7.3B | ||
| Q3 25 | $1.6B | $7.4B | ||
| Q2 25 | $1.5B | $7.6B | ||
| Q1 25 | $1.4B | $7.6B | ||
| Q4 24 | $1.6B | $7.7B | ||
| Q3 24 | $1.6B | $7.9B | ||
| Q2 24 | $1.6B | $7.9B | ||
| Q1 24 | $1.6B | $7.8B |
| Q4 25 | $3.4B | $12.2B | ||
| Q3 25 | $3.4B | $12.1B | ||
| Q2 25 | $3.3B | $12.4B | ||
| Q1 25 | $3.2B | $12.4B | ||
| Q4 24 | $3.3B | $12.4B | ||
| Q3 24 | $3.4B | $12.8B | ||
| Q2 24 | $3.4B | $13.4B | ||
| Q1 24 | $3.4B | $13.4B |
| Q4 25 | 0.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.39× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $355.8M | $182.0M |
| Free Cash FlowOCF − Capex | $326.3M | $161.8M |
| FCF MarginFCF / Revenue | 29.9% | 21.0% |
| Capex IntensityCapex / Revenue | 2.7% | 2.6% |
| Cash ConversionOCF / Net Profit | 1.43× | 1.85× |
| TTM Free Cash FlowTrailing 4 quarters | $1.1B | $509.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $355.8M | $182.0M | ||
| Q3 25 | $402.3M | $138.5M | ||
| Q2 25 | $185.7M | $134.3M | ||
| Q1 25 | $238.0M | $128.2M | ||
| Q4 24 | $262.0M | $174.2M | ||
| Q3 24 | $220.1M | $147.9M | ||
| Q2 24 | $248.3M | $158.6M | ||
| Q1 24 | $198.6M | $147.6M |
| Q4 25 | $326.3M | $161.8M | ||
| Q3 25 | $371.2M | $120.0M | ||
| Q2 25 | $151.6M | $115.5M | ||
| Q1 25 | $207.9M | $112.2M | ||
| Q4 24 | $232.8M | $149.8M | ||
| Q3 24 | $192.0M | $125.6M | ||
| Q2 24 | $215.0M | $136.6M | ||
| Q1 24 | $168.3M | $129.7M |
| Q4 25 | 29.9% | 21.0% | ||
| Q3 25 | 33.6% | 17.2% | ||
| Q2 25 | 13.7% | 16.0% | ||
| Q1 25 | 20.8% | 16.9% | ||
| Q4 24 | 24.4% | 20.5% | ||
| Q3 24 | 19.7% | 18.4% | ||
| Q2 24 | 21.4% | 19.7% | ||
| Q1 24 | 17.5% | 20.0% |
| Q4 25 | 2.7% | 2.6% | ||
| Q3 25 | 2.8% | 2.6% | ||
| Q2 25 | 3.1% | 2.6% | ||
| Q1 25 | 3.0% | 2.4% | ||
| Q4 24 | 3.1% | 3.4% | ||
| Q3 24 | 2.9% | 3.3% | ||
| Q2 24 | 3.3% | 3.2% | ||
| Q1 24 | 3.1% | 2.7% |
| Q4 25 | 1.43× | 1.85× | ||
| Q3 25 | 1.47× | 2.97× | ||
| Q2 25 | 0.63× | 2.49× | ||
| Q1 25 | 0.98× | 3.03× | ||
| Q4 24 | 1.21× | 1.84× | ||
| Q3 24 | 0.95× | 1.57× | ||
| Q2 24 | 1.22× | 2.87× | ||
| Q1 24 | 0.84× | 5.67× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
